Metsera Inc. (MTSR)
NASDAQ: MTSR
· Real-Time Price · USD
28.05
-0.63 (-2.20%)
At close: May 22, 2025, 3:59 PM
27.50
-1.96%
Pre-market: May 23, 2025, 09:11 AM EDT
-2.20% (1D)
| Bid | 27.5 |
| Market Cap | 2.95B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -161.21M |
| EPS (ttm) | -2.54 |
| PE Ratio (ttm) | -11.04 |
| Forward PE | -8.56 |
| Analyst | Buy |
| Ask | 27.72 |
| Volume | 1,275,640 |
| Avg. Volume (20D) | 962,603 |
| Open | 28.24 |
| Previous Close | 28.68 |
| Day's Range | 27.38 - 29.31 |
| 52-Week Range | 12.30 - 32.81 |
| Beta | -4.09 |
About MTSR
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MTSR
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MTSR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
+10.52%
Metsera shares are trading higher after the compan...
Unlock content with
Pro Subscription
1 month ago
+29.86%
Metsera shares are trading higher after Pfizer discontinued the development of danuglipron.
2 months ago · seekingalpha.com
Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 DifferentiationMetsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing and a strong safety profile. Positive phase 2a results for MET-097i showed signific...